|1.||Fairweather, I: 13 articles (06/2012 - 09/2005)|
|2.||Brennan, G P: 10 articles (06/2012 - 04/2007)|
|3.||Hanna, R E B: 8 articles (06/2012 - 08/2008)|
|4.||Keiser, Jennifer: 7 articles (09/2011 - 12/2005)|
|5.||Fairweather, Ian: 6 articles (10/2011 - 12/2007)|
|6.||Utzinger, Jürg: 6 articles (09/2011 - 12/2005)|
|7.||McConville, M: 5 articles (06/2012 - 04/2007)|
|8.||Edgar, H W J: 5 articles (06/2012 - 05/2008)|
|9.||Solana, H: 4 articles (10/2013 - 04/2007)|
|10.||Mas-Coma, Santiago: 3 articles (11/2013 - 11/2004)|
05/01/2014 - "The infection was successfully eliminated with the administration of triclabendazole. "
05/01/2012 - "The patient was in acute phase of infection and treated successfully with 10 mg/kg oral triclabendazole after the fluke was extracted using endoscopic retrograde cholangiopancreatography (ERCP)."
12/30/2012 - "gigantica infection has been confirmed and the diagnosed cases effectively treated with triclabendazole."
11/01/1991 - "The efficacy of triclabendazole (TCBZ) against natural infections with Fasciola gigantica was evaluated in a field study using 102 Indonesian cattle. "
07/01/2015 - "Treatment using a 2-day triclabendazole regimen cured the infection and signs of hepatic involvement disappeared. "
07/01/2012 - "Described here are the clinical, laboratory and radiological features of five pediatric fascioliasis cases with different clinical pictures presenting over a period of five years, all of whom were successfully cured with oral triclabendazole."
11/01/2004 - "1. A study performed > 10 years ago and case reports published recently suggest that triclabendazole is effective for the treatment of patients with fascioliasis. "
01/01/2012 - "Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano."
06/01/2007 - "To study the clinical efficacy of Triclabendazole (TCBZ) on Egyptian patients infected with Fasciola and understand the effect of Fascioliasis on the pharmacokinetics of TCBZ. "
11/01/2004 - "2. To confirm the efficacy of a human formulation of triclabendazole, we enrolled 165 patients into the present study and divided the subjects into two groups: (i) those who had fascioliasis, as evidenced by the presence of ova in their stools; and (ii) patients with clinical and laboratory data suggesting fascioliasis. "
|3.||Body Weight (Weight, Body)
01/01/1996 - "A study was conducted on the pharmacokinetics and therapeutic efficacy of triclabendazole at three low dose rates of 0.5, 1.0 and 1.5 mg/kg body weight in buffaloes experimentally infected with Fasciola gigantica. "
09/01/1983 - "A controlled test with 24 artificially-infected sheep revealed a 100% efficacy of triclabendazole at a dose of 10 mg kg-1 body weight against Fasciola hepatica aged 4 and 13 weeks, respectively. "
07/01/2015 - "The therapeutic scheme of triclabendazole (TCBZ), the recommended anthelmintic against Fasciola hepatica , involves 10mg/kg of body weight administered in a single dose; however, clinical trials in children are scarce. "
04/01/2015 - "Triclabendazole at a single dose of 10 mg/kg body weight is the treatment of choice."
07/01/2013 - "The animals were then treated with TCBZ (Fasinex(®) 10%) at 10mg/kg body weight. "
07/01/2003 - "Our findings show that both single-day treatment regimens of triclabendazole were highly effective in the treatment of pulmonary paragonimiasis and suggest that patients should be re-examined at 3 months to determine the need for repeat treatment."
11/01/2003 - "To observe triclabendazole effect on Paragonimus skrjabini in experimentally infected rats,and to develop a new drug for treating paragonimiasis. "
11/01/2003 - "Triclabendazole in the treatment of Paragonimiasis skrjabini."
07/01/2003 - "Comparison of two single-day regimens of triclabendazole for the treatment of human pulmonary paragonimiasis."
01/01/2001 - "Triclabendazole has marked therapeutic effect on paragonimiasis skrjabini. "
|3.||Drug Therapy (Chemotherapy)